Actively Recruiting

Age: 4Weeks +
All Genders
Healthy Volunteers
ID03739827

Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors

Led by National Cancer Institute (NCI) · Updated on 2026-06-08

10000

Participants Needed

3

Research Sites

200 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating rare solid tumors, which affect fewer than 150 people per million each year, including hereditary cancer syndromes. The goal is to better understand how these tumors develop, their clinical behavior, and genetic characteristics. This long-term observational study focuses on participants with rare tumors, their relatives, and carriers of genetic variants that predispose to these tumors to improve knowledge for screening, prevention, and treatments. Participants may provide medical history, family history, saliva samples, and possibly tumor tissue samples if they have a tumor. Some will undergo physical exams, clinical photography, blood, urine, saliva, and stool sample collection, specialist consultations, scans involving low radiation or magnetic fields, genetic testing, and counseling. The study also offers focus groups for those with similar diagnoses and may invite participants to join other related protocols. During the study, participants will be contacted yearly to update their medical and family history and report any tumor changes. Researchers review medical records, imaging, pathology, and genetic data while collecting patient-reported outcomes. The primary measurement is to evaluate the natural history and clinical course of rare solid tumors over a 10-year period. Active long-term follow-up is a key feature, aiming to maintain contact and provide insights for participants and the medical community.

CONDITIONS

Brief Title

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Who Can Participate

Age: 4Weeks +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants with a diagnosis of a rare solid tumor (fewer than 15 cases in 100,000 people per year), with no age restrictions beyond the neonatal period (4 weeks)
  • Participants without a rare tumor who have a germline genetic variant that predisposes to a rare solid tumor
  • Relatives of participants with diagnosis of rare solid tumors who do NOT have a known germline variant that predisposes to a rare solid tumor
  • Parent or guardian of child participating in a focus group if not already enrolled on the study
  • Ability of participant or legally authorized representative to understand and sign informed consent
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - Initial evaluation period varies

Participants provide clinical information and biospecimens for review, and if indicated, are invited for additional evaluations including clinical phenotyping, genotyping, imaging, and patient-reported outcomes.

1 or more visits depending on evaluation needs

Long-term Monitoring

Duration - Up to 10 years

Participants are followed longitudinally to evaluate the natural history of rare solid tumors or tumor predisposition syndromes, including ongoing collection of clinical data and biospecimens.

Ongoing visits as scheduled for follow-up and assessments

Trial Site Locations

Total: 3 locations

1

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Actively Recruiting

2

Oregon Health and Science University

Portland, Oregon, United States, 97239

Actively Recruiting

3

Texas Children's Hospital

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

B

Barbara J Thomas, R.N.

M

Mary F Wedekind Malone, D.O.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Similar Trials

A Phase 1/2 Open Label, Dose Escalation and Expansion Study ...

Advanced Solid Tumor

Actively Recruiting

27 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here